Search Results

Evecxia Therapeutics, Inc., the leader in serotonin synthesis amplification to treat brain disorders, today announced that Dr. Jacob Jacobsen has been appointed President and CEO.

Evecxia Therapeutics, Inc. today announced the appointments of Allan L. Shaw and Elliot Ehrich, MD to its Board of Directors, bringing with them decades of leadership experience in the biopharmaceutical industry.

Evecxia Therapeutics, Inc., the leader in serotonin synthesis amplification to treat brain disorders, today announced the absence of toxicity findings associated with the co-administration of EVX-101 in conjunction with the first-line antidepressant fluoxetine in nonclinical GLP toxicology studies.

Evecxia Therapeutics, Inc. today announced that the U.S. Patent and Trademark Office has allowed U.S. patent application 17/877,699.

Evecxia Therapeutics, Inc. today announced that an oral presentation, “The Therapeutic Potential of EVX-101 to Amplify Serotonin Synthesis for the Adjunctive Treatment of MDD and Other Mental Illness: Emerging Profile and Post-Phase 1 Update”, will be presented during the Pharmaceutical Pipeline Session on May 30th by Dr. Jacobson, Chief Scientific Officer, at the 2023 ASCP Meeting in Miami Beach, FL.

Evecxia Therapeutics, Inc. announced favorable safety, tolerability, pharmacokinetics, and pharmacodynamics data from a double-blind, placebo-controlled Phase 1 single ascending dose study of EVX-301 in healthy volunteers pre-treated with escitalopram for three weeks.